Bicara Therapeutics(BCAX)
BOSTON, MABiotechnology
Focus: Bicara Therapeutics is a publicly traded Boston-based biotech focused on dual-action biologics and antibodies for oncology, currently advancing a Phase 2/3 program in head and neck squamous cell carcinoma. The company operates at the clinical-stage level with a lean operational footprint.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
6-7 this month
Cooling — net -7 jobs in 30d
1 added, 8 removed. Slower than typical.
Should You Work at Bicara Therapeutics?
AI assessmentSuitable for early-stage oncology specialists willing to bet career on a dual-action mAb mechanism with meaningful cash cushion but single-asset risk profile.
Why Work Here
- Public company with $490M cash position (FY 2025) provides runway and equity upside opportunity without near-term dilution pressure.
- Early-stage oncology pipeline with dual-action biologic mechanism (Ficerafusp alfa in Phase 2/3) represents differentiated science with meaningful IP protection.
Data completeness
5/9 — Partial
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Slowing
Jobs decreasing
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PHASE_1
Clinical Trials (1)
NCT07807163A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
Phase 2Help build intelligence for Bicara Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.